SYDNEY and NEW YORK, May 26,
2015 /PRNewswire/ -- US-Australian drug discovery and
development company, Novogen Limited (ASX:NRT; NASDAQ:NVGN),
announced today that it will present at the 2015 Marcum MicroCap
Conference on Thursday, May 28, 2015
in New York City at the Grand
Hyatt Hotel.
The Company's presentation by Dr. Graham
Kelly, Novogen Chairman and CEO, is scheduled to begin at
9.30 a.m. ET and will be available
via a live webcast. To access the webcast, go to
http://wsw.com/webcast/marcum3/nvgn.
The annual Marcum MicroCap Conference is a showcase for public
companies with less than $500 million
in market capitalization. This year's keynote speaker will be
Richard S. Fuld, Jr., Chairman of
Matrix Advisors and former Chairman of Lehman Brothers.
For more information or to register, please visit the conference
website at http://www.marcumllp.com/microcap or download the free
official conference app for the iPhone, iPad, or for Android mobile
devices in Apple's App Store and the Google Play Market.
About the Marcum MicroCap Conference
The Marcum MicroCap Conference is dedicated to providing a forum
where publicly traded companies under $500
million in market capitalization can network with the
investment community. The conference features presentations by CEOs
and CFOs from six principal industry sectors and provides investors
with the opportunity to meet with management of these companies on
a one-on-one basis. Industry sectors include Technology,
Media & Internet; Software & Business Services; Life
Science & Healthcare; Retail & Consumer Products; Energy
& Natural Resources; and Industrials. The conference
additionally includes a full agenda of panel discussions on issues
of strategic importance to small cap issuers and investors,
moderated by industry leaders.
The Marcum MicroCap Conference attracts fund managers and high
net worth investors focusing on small cap equities. Over 2,000
participants from all segments of the microcap market attend each
year, including senior management, finance and legal executives,
venture and lower middle-market private equity investors,
institutional investors, directors, investment bankers, buy- and
sell-side analysts, and service providers to the microcap
marketplace.
For complete information about the 2015 Marcum MicroCap
Conference, visit www.marcumllp.com/microcap.
About Novogen
Novogen is a public, Australian-US drug development company
whose shares trade on both The Australian Securities Exchange (NRT)
and NASDAQ (NVGN). The Novogen group includes US-based, CanTx Inc,
a joint venture company with Yale
University. Novogen has two drug technology platforms
yielding drug candidates that are first-in-class with potential
application across a broad range of degenerative diseases. In the
oncology field, the ultimate objective is to see both drug
technologies used in combination as first-line therapy across most
forms of cancer, with the objective of preventing tumor recurrence.
This objective is based on a strategy of achieving comprehensive
destruction of the full hierarchy of cells within a tumor with the
super-benzopyran technology platform killing the tumor-initiating
cells and the anti-tropomyosin technology, combined with vinca
alkaloids, to deliver a potent chemical debulking effect on their
daughter cells.
For more information, please visit www.novogen.com
Corporate
Contact
|
Media
Enquiries
|
Dr. Graham
Kelly
|
Prue Kelly
|
Executive Chairman
& CEO
|
Media
Officer
|
Novogen
Group
|
Novogen
Group
|
Graham.Kelly@novogen.com
|
Prue.Kelly@novogen.com
|
+61 (0) 2 9472 4101
|
+61 (0) 2 9472 4101
|
Forward looking statement
All statements other than statements of historical fact
included in this announcement including, without limitation,
statements regarding future plans and objectives of Novogen Limited
("Novogen") are forward-looking statements. When used in this
announcement, forward-looking statements can be identified by words
such as 'may', 'could', 'should', 'would', 'believes', 'estimates',
'targets', 'expects' or 'intends' and other similar words that
involve risks and uncertainties.
Such statements relate to future events and expectations and
as such involve known and unknown risks and uncertainties. These
risks and uncertainties include, among other things, market
conditions, weather risks, economic and political risks.
These statements are based on an assessment of present
economic and operating conditions, and on a number of assumptions
regarding future events and actions that, as at the date of this
announcement, are expected to take place. Such forward-looking
statements are not guarantees of future performance and involve
known and unknown risks, uncertainties, assumptions and other
important factors, many of which are beyond the control of Novogen,
its directors and management, which could cause Novogen's actual
results to differ materially from the results expressed or
anticipated in these statements.
Novogen cannot and does not give any assurance that the
results, performance or achievements expressed or implied by the
forward-looking statements contained in this announcement will
actually occur and investors are cautioned not to place undue
reliance on these forward-looking statements. Actual results,
actions, and developments may differ materially from those
expressed or implied by those forward-looking statements depending
on a variety of factors.
Novogen does not undertake to update or revise forward-
looking statements, or to publish prospective financial information
in the future, regardless of whether new information, future events
or any other factors affect the information contained in this
announcement, except where required by applicable law and stock
exchange listing requirements.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/novogen-to-present-at-the-2015-marcum-microcap-conference-300088387.html
SOURCE Novogen Ltd